Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/12225
Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME (R)
Identifiers
ISSN: 1346-9843
eISSN: 1347-4820
WOS ID: 000395051800017
Scopus EID: 2-s2.0-85010749154
PMID: 28025462
Embase PUI: L614236180
Share
Statistics
Item usage statisticsMetadata
Show Dublin Core item recordAuthor
Kaku, Kohei; Lee, Jisoo; Mattheus, Michaela; Kaspers, Stefan; George, Jyothis; Woerle, Hans-Juergen; Aizenberg, D.; Ulla, M.; Waitman, J.; De Loredo, L.; Farias, J.; Fideleff, H.; Lagrutta, M.; Maldonado, N.; Colombo, H.; Ferre Pacora, F.; Wasserman, A.; Maffei, L.; Lehman, R.; Selvanayagam, J.; d'Emden, M.; Fasching, P.; Paulweber, B.; Toplak, H.; Luger, A.; Drexel, H.; Prager, R.; Schnack, C.; Schernthaner, G.; Fliesser-Goerzer, E.; Kaser, S.; Scheen, A.; Van Gaal, L.; Hollanders, G.; Kockaerts, Y.; Capiau, L.; Chachati, A.; Persu, A.; Hermans, M.; Vantroyen, D.; Vercammen, C.; Van de Borne, P.; Mathieu, C.; Benhalima, K.; Lienart, F.; Mortelmans, J.; Strivay, M.; Vereecken, G.; Keymeulen, B.; Lamkanfi, F.; Chacra, A.; Eliaschewitz, F.; Zanella, M.; Faludi, A.; Bertolami, M.; Hayashida, C.; Nunes Salles, J.; Monte, O.; Dinato, M.; Manenti, E.; Rassi, N.; Halpern, A.; Lima Filho, M.; Ayoub, J.; Felicio, J.; Borges, J.; Gross, J.; Sgarbi, J.; Betti, R.; Tiburcio, A.; Purisch, S.; Schmid, H.; Takahashi, M.; Castro, M.; Rea, R.; Hissa, M.; Geloneze Neto, B.; Saraiva, J.; Henein, S.; Lochnan, H.; Imran, S. A.; Clayton, D.; Bayly, K.; Berlingieri, J.; Boucher, P.; Chan, Y.; Gupta, M.; Chehayeb, R.; Ouellett, A.; Ur, E.; Woo, V.; Zinman, B.; St Amour, E.; Terront Lozano, M.; Yupanqui Lozno, H.; Urina, M.; Lopez Jaramillo, P.; Jaramillo, N.; Sanchez, G.; Perez, G.; Tusek, S.; Mirosevic, G.; Goldoni, V.; Jurisic-Erzen, D.; Balasko, A.; Balic, S.; Drvodelic-Sunic, E.; Varzic, S. Canecki; Machkova, M.; Weiner, P.; Lastuvka, J.; Olsovsky, J.; Krarup, T.; Ridderstrale, M.; Tarnow, L.; Boesgaard, T. Wellov; Lihn, A. Saetre; Christensen, P.; Juhl, H.; Urhammer, S.; Lund, P.; Adojaan, B.; Jakovlev, U.; Lanno, R.; Lubi, M.; Marandi, T.; Gouet, D.; Courreges, J.; Zaoui, P.; Choukroun, G.; Petit, C.; Formagne, L.; Estour, B.; Mabire, P.; Daugenet, C.; Lemarie, B.; Clavel, S.; Aure, P.; Remaud, P.; Halimi, J.; Hadjadj, S.; Couffinhal, T.; Glonti, S.; Metreveli, D.; Lominadze, Z.; Giorgadze, E.; Burtchuladze, T.; Javashvili, L.; Kurashvili, G.; Kurashvili, R.; Virsaladze, D.; Nadareishvili, L.; Khomasuridze, A.; Cahill, T.; Green, F.; MacRury, S.; Waldron, M.; Middleton, A.; McKnight, J.; Pearson, E.; Butler, M.; Choksi, M.; Caldwell, I.; Farmer, I.; Wyatt, N.; Patrick, J.; O'Brien, I.; Devers, M.; Bousboulas, S.; Pappas, S.; Piaditis, G.; Vryonidou, A.; Tentolouris, N.; Karamitsos, K.; Manes, C.; Benroubi, M.; Avramidis, I.; Ozaki, R.; Tan, K.; Siu, S.; Tsang, C.; Dudas, M.; Nagy, K.; Salamon, C.; Ip, T.; Geroo, L.; Patkay, J.; Tabak, A.; Juhasz, F.; Szentpeteri, I.; Tamas, G.; Ghaisas, N.; Bantwal, G.; Mohan, V.; Gupta, J.; Sadhu, N.; Kulkarni, A.; Garg, N.; Reddy, S.; Deshpande, N.; Gutlapalli, K.; Pillai, M.; Premchand, R.; Badgandi, M.; Jain, S.; Aravind, S.; Shamanna, P.; Pandey, A.; Gupta, S.; Pramono, B.; Saksono, H. Dante; Agung, P.; Wahono, S. Djoko; Suastika, K.; Tanggo, Y.; Juwana, Y.; Siswanto, B.; Adawi, F.; Efrati, S.; Mazen, E.; Bashkin, A.; Herskovits, T.; Jaffe, A.; Schiff, E.; Wainstein, J.; Taddei, S.; Aiello, A.; Arca, M.; Calabro, P.; Cignarelli, M.; Fioretto, P.; Reggiani, G. Marchesini; Gnasso, A.; Marchionni, N.; Marsilii, A.; Bucci, M.; Mezzetti, A.; Pozzilli, P.; Colivicchi, F.; Santini, M.; Moro, E.; Toscano, V.; Fucili, A.; Semplicini, A.; Monno, S.; Furui, K.; Higashiue, S.; Hiramatsu, N.; Kawamitsu, K.; Takenaka, T.; Takahashi, H.; Hojo, F.; Onishi, Y.; Izumino, K.; Okubo, M.; Wakida, Y.; Kondo, Y.; Hieshima, K.; Jinnouchi, H.; Suzuki, A.; Ito, M.; Park, S.; Kim, Y.; Hong, T.; Park, H.; Gwon, H.; Kim, H.; Kang, K.; Jeong, M.; Seung, K.; Lim, D.; Rha, S.; Tahk, S.; Yang, J.; Yoon, J.; Shin, M.; Kim, D.; Jeong, J.; Ahmad, N. Nik; Mustafa, N.; Mohamed, W. Wan; Fung, Y.; Ghani, R. Abdul; Chandramouli, A.; Chee, K.; Kadir, K. Abdul; Ling, K.; Abu Hassan, M.; Foo, S.; Lee, S.; Garcia Hernandez, P.; Aguilar-Salinas, C.; Vidrio Velazquez, M.; Flores, F.; Alpizar Salazar, M.; Micher Escalante, D.; Garcia Soria, M.; Cardona Munoz, E.; Storms, G.; Schaper, N.; Kooy, A.; Krekels, M.; van Bemmel, T.; Verhoeven, R.; Mulder, H.; Oldenburg-Ligtenberg, P.; Gonkel, F.; de Jong, A.; van Soest, J.; Viergever, P.; Mevissen, H.; Lochorn, G.; Zwiers, G.; Hoogslag, P.; Ronner, E.; Nierop, P.; Al-Windy, N.; Kragten, J.; Dekelver, P.; Benatar, J.; Krebs, J.; Scott, R.; Heggen, E.; Berz, A.; Fossum, C.; Hurtig, U.; Langslet, G.; Baranowski, M.; Sparby, J.; Karlsson, T.; Karlsson, Thomas; Delgado Torres, C.; Rodriguez Escudero, A.; Lisson, R.; Allemant Maldonado, A.; Gallardo Rojas, W.; Gonzales Bravo, L.; Lema Osores, J.; Farfan, J.; Zapata, L.; Godoy Junchaya, J.; Roldan Concha, Y.; Urquiaga Calderon, J.; Sy, R.; Tan, G.; Aquitania, G.; De Los Santos, G.; Panelo, A.; Roderos, O.; Rosales, R.; Toledo, R.; Liwag, A.; Ramoncito, H.; Skokowska, E.; Krzyzagorska, E.; Ogorek, M.; Wojnowski, L.; Spyra, J.; Konieczny, M.; Piesiewicz, W.; Kus, W.; Ocicka-Kozakiewicz, A.; Orlowska-Kunikowska, E.; Zmuda, W.; Duarte, S.; Leitao, A.; Monteiro, P.; Rita, H.; Salgado, V.; Pinto, L.; Queiros, J.; Teixeira, J.; Rogado, C.; Duarte, R.; Sobral do Rosario, F.; Silva, A.; Andrade, L.; Velez, M.; Brazao, M.; Istratoaie, O.; Lichiardopol, R.; Catrinoiu, D.; Militaru, C.; Zetu, C.; Barbonta, D.; Cosma, D.; Crisan, C.; Pop, L.; Esip, V.; Khetagurova, F.; Petrov, A.; Arutyunov, G.; Boyarkin, M.; Agafyina, A.; Vorokhobina, N.; Petunina, N.; Libov, I.; Zalevskaya, A.; Nikolaev, K.; Barbarash, O.; Potemkin, V.; Bystrova, A.; Krasilnikova, E.; Barbarich, V.; Chumakova, G.; Tarasov, N.; Meleshkevich, T.; Zateyshchikov, D.; Lantseva, O.; Belenkiy, D.; Obrezan, A.; Rossolko, L.; Fillipova, E.; Yakhontova, P.; Khokhlov, A.; Tan, R.; Sum, C.; Chang, H.; Distiller, L.; Pretorius, M.; Nortje, H.; Mitha, E.; Burgess, L.; Blignaut, S.; Venter, T.; Moodley, R.; Lombaard, J.; Govind, U.; Naidoo, V.; Mookadam, M.; Engelbrecht, J.; Omar, M.; Jurgens, J.; Podgorski, G.; Vawda, H.; Naidoo, D.; Emanuel, S.; Roodt, A.; Amod, A.; Van Zyl, L.; Segura, J.; Brito, M.; Fernandez-Cruz, A.; Artola, S.; Iglesias, R.; Toural, E.; Garcia-Ortiz, L.; Saban, J.; Mesa, J.; Vidal, J.; Linares, J.; del Canizo, F.; Rigla, M.; Suarez, C.; Llorente, I.; Moreno, B.; Antoli, A.; Gomez Peralta, F.; Iglesias, M.; Pereg Macazaga, Vicente
Publication date
2017-02Document type
research articleCitation
Kaku Kohei, Lee Jisoo, Mattheus Michaela, Kaspers Stefan, George Jyothis, Woerle Hans-Juergen, et al. Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME (R). Circ J. 2017 Feb;81(2):227-+. Epub 2016 Dec 23.Abstract
Background: In the EMPA-REG OUTCOME (R) trial, empagliflozin added to standard of care reduced the risk of 3-point major adverse cardiovascular (CV) events (3-point MACE: composite of CV death, non-fatal myocardial infarction, or non-fatal stroke) by 14%, CV death by 38%, hospitalization for heart failure by 35%, and all-cause mortality by 32% in patients with type 2 diabetes (T2DM) and established CV disease. We investigated the effects of empagliflozin in patients of Asian race. Methods and Results: Patients were randomized to receive empagliflozin 10 mg, empagliflozin 25 mg, or placebo. Of 7,020 patients treated, 1,517 (21.6%) were of Asian race. The reduction in 3-point MACE in Asian patients was consistent with the overall population: 3-point MACE occurred in 79/1,006 patients (7.9%) in the pooled empagliflozin group vs. 58/511 patients (11.4%) in the placebo group (hazard ratio: 0.68 [95% confidence interval: 0.48-0.95], P-value for treatment by race interaction (Asian, White, Black/African-American): 0.0872). The effects of empagliflozin on the components of MACE, all-cause mortality, and heart failure outcomes in Asian patients were consistent with the overall population (P-values for interaction by race >0.05). The adverse event profile of empagliflozin in Asian patients was similar to the overall trial population. Conclusions: Reductions in the risk of CV outcomes and mortality with empagliflozin in Asian patients with T2DM and established CV disease were consistent with the overall trial population.
Publisher version
https://dx.doi.org/10.1253/circj.CJ-16-1148MeSH
Cardiovascular DiseasesDiabetes Mellitus, Type 2
Aged
Benzhydryl Compounds
Humans
Asian Continental Ancestry Group
Middle Aged
Stroke
Glucosides
Hypoglycemic Agents
Myocardial Infarction
Male
Female
Treatment Outcome
DeCS
Resultado del TratamientoAccidente Cerebrovascular
Femenino
Infarto del Miocardio
Grupo de Ascendencia Continental Asiática
Masculino
Glucósidos
Hipoglucemiantes
Humanos
Persona de Mediana Edad
Anciano
Diabetes Mellitus Tipo 2
Compuestos de Bencidrilo
Enfermedades Cardiovasculares